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Design of allosteric stimulators of the HSP90 ATPase as novel 
anticancer leads 
Ilda D’Annessa [a], Sara Sattin[b], Jiahui Tao[c], Marzia Pennati[d], Carlos Sànchez-Martìn[e], Elisabetta 
Moroni[f], Andrea Rasola[e], Nadia Zaffaroni[d], David A. Agard[c], Anna Bernardi[b] and Giorgio 
Colombo*[a] 
Abstract: We rationally designed allosteric compounds that 
stimulate Hsp90 ATPase activity and show anticancer potencies 
in the low micromolar to nanomolar range. In parallel, we clarify 
their mode of action and developed a quantitative model that 
links the dynamic ligand-protein cross-talk to observed cellular 
and in vitro activities. Our results support the potential of using 
dynamics-based approaches to develop original mechanism-
based cancer therapeutics. 
 
Heat Shock Protein 90 (Hsp90) is a chaperone that controls the 
folding of more than 200 client proteins and constitutes a central 
node in many signaling pathways[1]. Overexpression and 
dysregulation of Hsp90 have been linked with cancer and 
neurodegeneration. It is thus not surprising that this chaperone 
has become an important drug-target: in principle its inhibition 
can result in the simultaneous degradation of multiple clients 
associated with different pathological hallmarks[2]. Inhibitors 
targeting the N-terminal ATP-binding site have been developed 
and some reached clinical trials [3]. However, they all showed 
problems due to the induction of the HSF1 mediated heat shock 
response and of Hsp70 overexpression, leading to drug 
resistance and toxicity[3a-c, 4].  
A viable alternative to interfering with Hsp90 is represented by 
allosteric ligands, which perturb the chaperone by targeting sites 
alternative to the ATP-site. Novobiocin was shown to inhibit 
Hsp90 by binding the C-terminal region without inducing the 
heat shock response. Based on this observation, a number of 
new derivatives with promising activities against a variety of 
cancers were developed[5]. 
In this context, we have developed a method for the 
identification of allosteric pockets via the analysis of residue-pair 
distance fluctuations in the structural ensemble around the 
active state of the chaperone. Such analysis unveiled an 
allosteric pocket at 65Å from the active site, located at the 
MD:CTD border in a region in close proximity to the client 
binding site[6]. This facilitated the design of modulators showing 
promising anticancer activities and a novel molecular 
mechanism of perturbation of Hsp90 functions: the ligands in 
fact were synthesized and experimentally proved to be 
activators of closure kinetics and ATPase of the chaperone in 
vitro, to induce cancer cell death, and to interfere with client 
maturation[6b]. We developed a first Quantitative-Structure-
Dynamics-Activity-Relationship (QSDAR) model correlating the 
structures of an initial set of modulators to observed activation 
effects[6c].  
Here, based on this initial model, we report the rational design 
and synthesis of new allosteric ligands, reaching low micromolar 
to nanomolar anticancer activities, which support their potential 
in the development of anticancer therapeutics. On the 
computational side, we further develop a model to evaluate the 
potency of allosteric modulators by taking into account the 
dynamic cross-talk that exists between the protein and the 
ligand.  
 
The conformational properties of the allosteric site were 
previously described [6-7]. Docking, MD refinement and analysis 
of the allosteric effects of the lead O-aryl rhamnoside 
benzofuran 1 revealed that the glycosidic moiety preferentially 
interacted with E477 and D503 of one protomer, while the 
propenyl substituent on the benzofuran could contact a 
hydrophobic pocket lined by R591 of the other protomer. This 
model led to redesigning 1 into 18 and 19 (Table 1) where the 
sugar moiety was replaced by an N,N-dimethyil-ethylamino or a 
propylamino group. Substitution of the propenyl group by a Cl 
atom was initially explored for synthetic convenience and proved 
to be beneficial in terms of solubility and activity,[6b] therefore it  
was maintained for 18 and 19. Such modification resulted in an 
improved anticancer cytotoxicity of the ligands. A new round of 
MD simulations and allosteric coordination analysis supported 
the importance of interactions with E477 and D503 [6b, c]. Here, to 
establish structure-dynamics-activity relationships, in the 
absence of crystal structures difficult to obtain due to the 
flexibility of the system, we directed design efforts towards 
obtaining different amine substitutions on the phenyl-benzofuran 
scaffold. The structures of the compounds are reported in Table 
1, representative examples of their best poses in the Hsp90 
pocket are shown in Figure 1A, and the details of their synthesis 
are described in a previous report[8]. 
All compounds resulted in activation of ATP hydrolysis, with the 
activity depending on the nature of the substituent linked to the 
O-aryl moiety (Table 1). Compounds 20-23, characterized by the 
presence of a bulky substituent on the amino group, display the 
lowest activity. The compounds 22 and 23 with an N-methyl 
piperazine group on the phenol side chain, stimulate ATPase to 
a degree comparable to that induced by the glycosidic 
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derivatives previously tested[6b,c], suggesting that the 6-
membered ring actually mimics sugar substituents. Maximal 
stimulatory effects were observed for 24, 25 and 26 indicating 
that minimizing the steric hindrance on the amine-
pharmacophore, while maintaining its alkylation, is beneficial to 
ATPase stimulation, resulting in a 4-5 fold increase [6-7].  
 
 
Table 1. Structures, stimulatory potencies and cytotoxic activities of 
designed compounds. ATPase stimulation and cytotoxicity were measured 
as described in Materials and Methods in Supporting Information. 
Compound 
Normalized 
ATPase rate 
Toxicity in 
STO 
(IC50 µM) 
1 
 
1.1a 57.0 ± 2.1a 
18 
 
4.8a 8.9 ± 1.1a 
19 
 
6a 9.9 ± 1.1a 
20 
 
1.5 16 ± 1 
21 
 
2.2 8.2 ± 2.7 
22 
 
1.9 11.7 ± 2.4 
23 
 
2.4 3.9 ± 1.8 
24 
 
4.1 8.6 ±2.1 
25 
 
4.5 22.1 ± 1.1 
26 
 
4.2 4.1 ± 0.4 
27 
 
1.4 not soluble 
28 
 
1.3 36 ± 6 
29 
 
1.17 > 75 
30 
 
0.98 > 100 
31 
 
- 0.57±0.04 
[a] a Data reported in [6b] 
 
Finally, compounds 28-30, that carry a carboxylate group 
tethered to the benzofuran moiety, while conserving the N,N-
dimethyl amino pharmacophore on the phenol ring showed a 
decreased stimulation compared to 24-26. The structural reason 
for this effect is to be found in the fact that the hydrophobic 
region on protomer A occupied originally by the propenyl or 
chloride groups is lined by negatively charged residues E477 
and D503 (blue in Figure 1): this determines unfavorable 
repulsive interactions with the carboxylates, which are 
detrimental to activity.  
Given the importance of Hsp90 in determining cancer 
maintenance and development, we tested the antiproliferative 
activity of the new compounds in an experimental model of 
diffuse malignant peritoneal mesothelioma (STO), an uncommon 
and locally aggressive tumor, poorly responsive to conventional 
therapies [9]. 
 
Figure 1. (A) Overall view and detailed superposition of the best pose for each 
compound in the allosteric site. Color code: Protomers A and B, light blue and 
green respectively; compounds: C=grey, O=red, N=blue, Cl=green, F=dark 
yellow. (B) Best pose obtained for compound 25, in red, showing the highest 
ATPase stimulation. The side chains of residues interacting with 25 are shown 
with the color code reported in (A). (C) Same as (B), reporting compound 22 in 
orange, displaying lowest stimulation. 
 
Cells were exposed to increasing concentrations (0.01-100 µM) 
of each compound for 72 hours, and the effect on cell 
proliferation was assessed by MTS assay. STO cells were highly 
responsive to compounds 23, 24, and 26, as indicated by the 
IC50 of 3.9±1.8, 8.6±2.1, and 4.1±0.4µM, respectively. A slightly 
less pronounced effect was observed after exposure of STO 
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cells to compounds 22 and 25, highlighting the relevance of alkyl 
substitutions on the amino groups to increase the 
antiproliferative activity. By contrast, the presence of the 
negatively charged carboxylate group led to a decreased (28) or 
null (29 and 30) activity (Table 1). 
Interestingly, a remarkable antiproliferative effect (0.57±0.04µM) 
was observed for compound 31 (Table 1), obtained by replacing 
the N,N-dimethylamino group of 19 with a triphenylphosphonium 
group. This substituent is expected to improve cell and 
mitochondrial penetration [10]. For this molecule, we also 
analyzed the ability to modulate the Hsp90 mitochondrial 
homologue TRAP, by measuring the activity of succinate 
dehydrogenase in human cervix carcinoma HeLa cells, which is 
inhibited by TRAP1. Indeed, compound 31 decreases the 
activity of the enzyme in a dose-dependent way (Figure 2) as 
expected for a potential TRAP1 activator [11]. As a possible 
caveat, it is worth noting that we are assuming that TRAP1 is 
targeted by the compound in a similar way to Hsp90.  
 
Figure 2. Analysis of the Sulfide-Quinone Reductase (SQR) enzymatic activity 
of succinate dehydrogenase in human cervix carcinoma HeLa cells pretreated 
for 30 minutes with compound 31 at the reported concentrations. Data are 
reported as mean ± SD values (n = 3); asterisks indicate significant differences 
(*** for a p<0.01 with a Student's t test analysis). 
Because the designed compounds target a dynamic allosteric 
site on Hsp90 that does not overlap with and is far removed from 
the ATP binding site, it is expectedly hard to obtain correlations 
between computationally determined affinities and effects on 
chaperone functions or cellular activities [12].  
To define a quantitative relationship between the ligands’ 
structures, dynamics cross-talk with the protein and observed 
activities, we made use of an ensemble approach[6c]: we docked 
each of the ligands into the ten most representative structures 
extracted upon clusterization of Hsp90 MD trajectories (see 
Supplementary Methods). For each ligand, we ranked the best 
pose from the 10 runs, and for each run the pose with the best 
docking score was selected for further calculations.  This 
method allows to describe the recognition event in terms of an 
esnamble of ligand poses interacting with an ensemble of 
(dynamic) protein structures. Superposition of the best pose 
selected for each ligand is reported in Figure 1A. All the 
compounds are characterized by interactions with the same set 
of residues: E477 interacts with the amine in all compounds, but 
it also binds the OH group of the phenol ether side-chain in 
compounds 24 (not shown) and 25 (Figure 1B). The O-aryl 
moiety contacts R591 of the same protomer. Compounds 22 
(Figure 1C) and 23 (data not shown) interact with D503 (Figure 
1C), as observed previously for O-aryl-sugars [6b, c]. The 
benzofuran moiety mainly establishes pi-cation interactions with 
K594 from the other protomer in all the ligands. 
 
Next, we calculated Dynamic Ligand Efficiency (DLE). i.e. the 
Ligand Efficiency in a multiconformational protein ensemble[6c], 
see Supp. Information, to correlate predicted docking scores to 
ATPase stimulation and cellular effects. 31 was not included in 
this list, as its fluorescence prevented measuring ATPase. In 
Supplementary Figure 1 (SF1), we report the correlation 
between the DLE of the set of newly designed compounds 
together with the ones previously described in [6c]. The model 
provides a good correlation between DLEs and measured 
ATPase stimulations (R = -0.66 considering all compounds 
discussed here and in [6c]; R = -0.71 when considering only co-
generic amino-derivatives). This finding supports the validity of 
our model for the design of allosteric activators of Hsp90. Next, 
we assessed the capacity of our new DLE descriptor to evaluate 
the potency of the designed compounds in antiproliferative 
assays. Importantly, the calculated DLE shows a significant 
correlation with measured cytotoxicities against the cancer STO 
cell line, with correlation value of 0.62 when considering the 
whole series, which raises to 0.67 when considering only amines 
(see Table 1; SF1) indicating the ability of this very simple model 
to quantitatively capture the main determinants of cytotoxic 
activities. 
 
To the best of our knowledge, these results are the first that 
show the actual feasibility of pushing integrated knowledge of 
dynamic protein-ligand cross-talk into the design of new Hsp90 
allosteric compounds, with novel functional impacts as well as 
improved antiproliferative activities. We have shown before [6b] 
that these compounds stimulate Hsp90 ATPase activity by 
accelerating the protein conformational cycle and favoring the 
catalytically active state: we hypothesize that this reverberates in 
a modification of the population of the chaperone structural 
ensembles and of the timing with which Hsp90 conformational 
families are presented to interaction with co-chaperones and 
clients. Consistent with recent findings based on mutational 
studies [6b, 13], this novel way of perturbing chaperone 
populations and kinetics can expectedly be detrimental to cell 
viability. It should be noted here that Hsp90 expression in tumor 
cells can reach up to the 4-7% of the expressed proteome. A 
marked increase in its chaperone activity might induce loss of 
homeostatic and feedback controls in a variety of oncogenic 
signal transduction pathways finely-tuned by Hsp90. Moreover, 
an excess Hsp90 activity could prompt proteostatic and 
bioenergetic stress in neoplastic cells by affecting the 
proteasomal degradation of several client proteins and by 
causing a harmful drop in ATP levels. These considerations, 
combined to further tests of the novel series of molecules, may 
open new perspectives for Hsp90 based therapeutics. In 
conclusion, our compounds may represent a new series of 
Hsp90 modulators as anticancer drugs with a novel mechanism 
of action based on the perturbation of the conformational 
population and kinetics of the Hsp90 machinery. 
Experimental Section 
Experimental Details are reported in the accompanying Supplementary 
Information 
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